Mesoblast Analyst Price Targets - Benzinga

Mesoblast Ltd

MESONASDAQ

Trade with Public

Trade with Public

$14.22

0.140.99%

最終更新: Oct 5, 4:49 PM

$14.50

0.422.98%

概要ニュース業績予想イベント目標株価財務センチメント株主構成比較オプション株式レポート

Mesoblast Analyst Price Targets - Benzinga

Mesoblast Analyst Price Targets

Wall Street analyst price targets and consensus rating for Mesoblast (MESO).

Price Target Range — 4 Quarters

Analyst Consensus — 4 Analysts

4Buy

Consensus RatingBuy# Analysts4Avg. Consensus PT$26Upside to Avg. PT+75.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 27, 2026	Piper Sandler	Edward Tenthoff	PT Raise	Overweight	$35→$39
Nov 25, 2025	Jefferies	David Stanton	Upgrade	Hold→Buy	—
Jul 18, 2025	Jefferies	David Stanton	Downgrade	Buy→Hold	—
Feb 7, 2025	Piper Sandler	Edward Tenthoff	PT Raise	Overweight	$15→$24
Dec 23, 2024	Jefferies	David Stanton	Downgrade	Buy→Hold	—
Dec 19, 2024	Piper Sandler	Edward Tenthoff	PT Raise	Overweight	$11→$15
Sep 24, 2024	Maxim Group	Jason McCarthy	Upgrade	Hold→Buy	$12
Aug 29, 2024	Jefferies	David Stanton	Upgrade	Hold→Buy	—
Aug 29, 2024	Cantor Fitzgerald	Louise Chen	Maintained	Overweight	—
Jul 23, 2024	Piper Sandler	Edward Tenthoff	Upgrade	Neutral→Overweight	$4→$11
Jun 20, 2024	Cantor Fitzgerald	Louise Chen	Maintained	Overweight	—
Jun 4, 2024	Cantor Fitzgerald	Louise Chen	Maintained	Overweight	—

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Piper Sandler Reiterates Overweight on Mesoblast, Raises Price Target to $39

Piper Sandler analyst Edward Tenthoff reiterates Mesoblast (NASDAQ:MESO) with a Overweight and raises the price target from $35 to $39.

Benzinga Newsdesk

This Brinker International Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

Avi Kapoor

PRO
Jefferies Upgrades Mesoblast to Buy

Jefferies analyst David Stanton upgrades Mesoblast (NASDAQ:MESO) from Hold to Buy.

Benzinga Newsdesk

This Elevance Health Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

Avi Kapoor

PRO
Jefferies Downgrades Mesoblast to Hold

Jefferies analyst David Stanton downgrades Mesoblast (NASDAQ:MESO) from Buy to Hold.

Benzinga Newsdesk

PRO
Piper Sandler Reiterates Overweight on Mesoblast, Raises Price Target to $24

Piper Sandler analyst Edward Tenthoff reiterates Mesoblast (NASDAQ:MESO) with a Overweight and raises the price target from $15 to $24.

Benzinga Newsdesk